Updated Jul 16, 2026
Hansen Gwenn has filed 2 SEC Form 4 filings across 1 company in the last 90 days — selling. Lifetime open-market sales: $378K.
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-25 | NRIX | Nurix Therapeutics, Inc. | S — Open-market sale | 5.4K | $20.00 | $108K |
| 2026-04-30 | NRIX | Nurix Therapeutics, Inc. | S — Open-market sale | 3.2K | $16.65 | $53K |
| 2026-04-30 | NRIX | Nurix Therapeutics, Inc. | M — Option exercise | 2.9K | $0.00 | |
| 2026-04-30 | NRIX | Nurix Therapeutics, Inc. | M — Option exercise | 3.8K | $0.00 | |
| 2026-04-30 | NRIX | Nurix Therapeutics, Inc. | M — Option exercise | 2.0K | $0.00 | |
| 2026-02-04 | NRIX | Nurix Therapeutics, Inc. | M — Option exercise | 31.3K | $0.84 | $26K |
| 2026-01-31 | NRIX | Nurix Therapeutics, Inc. | S — Open-market sale | 98 | $17.37 | $2K |
| 2026-01-31 | NRIX | Nurix Therapeutics, Inc. | S — Open-market sale | 4.8K | $16.58 | $80K |
| 2026-01-31 | NRIX | Nurix Therapeutics, Inc. | M — Option exercise | 2.9K | $0.00 | |
| 2026-01-31 | NRIX | Nurix Therapeutics, Inc. | M — Option exercise | 3.8K | $0.00 | |
| 2026-01-31 | NRIX | Nurix Therapeutics, Inc. | M — Option exercise | 2.0K | $0.00 | |
| 2026-01-31 | NRIX | Nurix Therapeutics, Inc. | M — Option exercise | 3.2K | $0.00 | |
| 2025-07-30 | NRIX | Nurix Therapeutics, Inc. | S — Open-market sale | 4.3K | $12.01 | $52K |
| 2025-07-30 | NRIX | Nurix Therapeutics, Inc. | M — Option exercise | 2.9K | $0.00 | |
| 2025-07-30 | NRIX | Nurix Therapeutics, Inc. | M — Option exercise | 3.8K | $0.00 | |
| 2025-07-30 | NRIX | Nurix Therapeutics, Inc. | M — Option exercise | 2.0K | $0.00 | |
| 2025-07-30 | NRIX | Nurix Therapeutics, Inc. | M — Option exercise | 3.2K | $0.00 | |
| 2024-10-30 | NRIX | Nurix Therapeutics, Inc. | S — Open-market sale | 3.4K | $24.30 | $84K |
| 2024-10-30 | NRIX | Nurix Therapeutics, Inc. | M — Option exercise | 3.8K | $0.00 | |
| 2024-10-30 | NRIX | Nurix Therapeutics, Inc. | M — Option exercise | 2.0K | $0.00 |
Hansen Gwenn is a corporate insider — currently tracked as Chief Scientific Officer of Nurix Therapeutics, Inc. (NRIX). InsiderAlpha tracks every SEC Form 4 filing in real time.
2 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 6 open-market sales ($378K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Hansen Gwenn profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.